Clinical trial
A Phase 2 Study of Pembrolizumab in Patients With Histiocyte/Dendritic Cell Neoplasms and Biologically Selected Subtypes of Relapsed/Refractory Aggressive Lymphomas
NCT03316573 is registered in ClinicalTrials.gov with Dana-Farber Cancer Institute as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2 Study of Pembrolizumab in Patients With Histiocyte/Dendritic Cell Neoplasms and Biologically Selected Subtypes of Relapsed/Refractory Aggressive Lymphomas
- Lead sponsor
- Dana-Farber Cancer Institute
- Phase
- Phase 2
- Overall status
- Suspended
- Start date
- December 7, 2017
- Completion date
- December 1, 2026
- Enrollment
- 18 (actual)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.
follicular dendritic cell sarcoma, histiocytic sarcoma, interdigitating dendritic cell sarcoma, lymphoma